Johnson & Johnson : to Host Fourth-Quarter/ Full-Year 2014 Investor Conference Call on Results
December 17, 2014 at 11:13 am EST
Share
NEW BRUNSWICK, NJ (Dec. 17, 2014) - Johnson & Johnson (NYSE: JNJ) will host a conference call at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 20, to discuss fourth-quarter and full-year 2014 financial results. Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; Dominic J. Caruso, Vice President, Finance and Chief Financial Officer; and Louise Mehrotra, Vice President, Investor Relations will host the call.
Investors and other interested parties may access the conference call in the following ways:
At Johnson & Johnson's website: www.investor.jnj.com. This earnings webcast is optimized for mobile streaming on iOS devices such as iPhones, iPods, and iPads. A webcast and podcast replay will be available approximately two hours after the conference call concludes.
By telephone: For both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 866-247-1020. For participants outside the U.S., the dial-in number is 804-419-7662. The conference ID number for all callers is 51855400. A replay of the conference call will be available beginning at approximately 12:00 p.m. on Jan. 20, 2015, and ending at approximately 12:00 a.m. on Jan. 27, 2015. The replay dial-in number for U.S. participants is 855-859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay conference ID number for all callers is 51855400.
Presentation materials will be available on www.investor.jnj.com.
About Johnson & Johnson
Caring for the world, one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
JOHNSON & JOHNSON 
